Thymosin Alpha 1 Cut Severe COVID-19 Death Rate from 30% to 11% by Restoring T Cell Function
Thymosin alpha 1 reduced mortality in severe COVID-19 patients from 30% to 11% by reversing lymphocytopenia and T cell exhaustion through enhanced thymic output.
Quick Facts
What This Study Found
Tα1 reduced severe COVID-19 mortality from 30% to 11.1% (P=.044), restored CD4+ and CD8+ T cell counts, and reversed T cell exhaustion markers (PD-1, Tim-3).
Key Numbers
Mortality 11.11% vs 30.00% (p=0.044); benefit threshold CD8+ <400/uL or CD4+ <650/uL; reduced PD-1 and Tim-3 on CD8+ T cells
How They Did This
Retrospective review of 76 severe COVID-19 patients from 2 Wuhan hospitals (Dec 2019-Mar 2020). Tα1-treated vs untreated; measured: mortality, T cell counts, TRECs (thymic output), PD-1 and Tim-3 expression on CD8+ T cells by flow cytometry.
Why This Research Matters
Severe COVID-19 kills partly through immune exhaustion. A peptide that restores T cell function rather than suppressing immunity addresses the root cause — and may apply to other viral infections.
The Bigger Picture
Thymosin alpha 1 has been used for decades in viral hepatitis. Its success in COVID-19 reinforces the concept that immune restoration — not just antiviral drugs — can save lives in severe infections.
What This Study Doesn't Tell Us
Retrospective non-randomized study — potential selection bias; small sample (76); single-center data from early pandemic (Dec 2019-Mar 2020); no standardized treatment protocol.
Questions This Raises
- ?Would a randomized controlled trial confirm the mortality benefit?
- ?Can Tα1 be used prophylactically for high-risk patients before severe disease develops?
- ?Does Tα1 benefit patients with other viral infections that cause lymphocytopenia?
Trust & Context
- Key Stat:
- 30% → 11.1% mortality Tα1 treatment nearly tripled survival in severe COVID-19 patients (P=.044)
- Evidence Grade:
- Moderate-high — significant mortality reduction with mechanistic immunological data, but limited by retrospective non-randomized design.
- Study Age:
- Published in 2020 from early pandemic data; subsequent COVID-19 treatments have evolved significantly.
- Original Title:
- Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.
- Published In:
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(16), 2150-2157 (2020)
- Authors:
- Liu, Yueping, Pan, Yue, Hu, Zhenhong, Wu, Ming, Wang, Chenhui, Feng, Zeqing, Mao, Congzheng, Tan, Yingjun, Liu, Ying, Chen, Li, Li, Min, Wang, Gang, Yuan, Zilin, Diao, Bo, Wu, Yuzhang, Chen, Yongwen
- Database ID:
- RPEP-04963
Evidence Hierarchy
Frequently Asked Questions
What is thymosin alpha 1?
A natural peptide produced by the thymus gland that helps mature and activate T cells. The synthetic version (Zadaxin) has been used for decades to boost immune function in chronic viral infections.
Who benefited most?
Patients with severely depleted immune cells — specifically those with CD8+ T cells below 400/µL or CD4+ T cells below 650/µL — gained the most benefit from Tα1 treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04963APA
Liu, Yueping; Pan, Yue; Hu, Zhenhong; Wu, Ming; Wang, Chenhui; Feng, Zeqing; Mao, Congzheng; Tan, Yingjun; Liu, Ying; Chen, Li; Li, Min; Wang, Gang; Yuan, Zilin; Diao, Bo; Wu, Yuzhang; Chen, Yongwen. (2020). Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(16), 2150-2157. https://doi.org/10.1093/cid/ciaa630
MLA
Liu, Yueping, et al. "Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. https://doi.org/10.1093/cid/ciaa630
RethinkPeptides
RethinkPeptides Research Database. "Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus..." RPEP-04963. Retrieved from https://rethinkpeptides.com/research/liu-2020-thymosin-alpha-1-reduces
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.